Ascent Scientific launches Amyloid β peptide isoforms - supporting Alzheimer's research
Amyloid-beta Peptide isoforms, Low-Cost Ligands™,
Alzheimer's disease is the most common form of dementia which has no known cure and is thought to be caused by pathogenicity induced by an increased production of β-amyloid peptide. Although the mechanisms involved are not yet fully understood, it is known that β amyloid peptide forms the main constituent of amyloid plaques - characteristically found in Alzheimer's disease patients.
In order to support Alzheimer's disease research, Ascent Scientific has launched a number of amyloid β peptide isoforms:
Amyloid β (1-42) (human)
42-residue amyloid β-protein fragment; the predominant form of amyloid β found in the brains of people with Alzheimer's disease and Down's syndrome. Neurotoxic. Shown to induce neuronal death via actions at the p75 neurotrophin receptor.
Amyloid β (1-40) (human)
One of the two main alloforms of the amyloid β peptide widely implicated in Alzheimer's disease. Displays neuroprotective properties preventing neuronal death.
Amyloid β (25-35) (human)
Highly toxic, synthetic peptide fragment of the amyloid β protein. Displays extremely rapid aggregation and enhanced neurotoxicity. Increases oxidative stress, causes neuronal damage and decreases spatial memory in rats.
Amyloid β (42-1) (human)
Inactive control for Amyloid β (1-42) peptide (Asc-301), the predominant form of amyloid β implicated in Alzheimer's disease.
Amyloid-beta Peptide isoforms
, Low-Cost Ligands™